Literature DB >> 8473395

The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.

L R Garibaldi1, T Aceto, C Weber, S Pang.   

Abstract

We used the GnRH agonist (GnRHa) stimulation test (20 micrograms/kg leuprolide sc, followed by 24-h serial sampling) to investigate the relationship between gonadotropin and estradiol (E2) secretion in the early phase of female central precocious puberty (CPP). Girls with CPP and moderately increased (early pubertal) peak E2 concentrations after GnRHa stimulation (136 +/- 11 pmol/L; range, 92-176; group B; n = 7) were compared to girls with CPP and higher (midpubertal) peak E2 responses to GnRHa (mean +/- SE, 590 +/- 63 pmol/L; range, 235-1189; group C; n = 19) and to a group of subjects with no breast development and a prepubertal hypothalamic-pituitary-gonadal axis (peak E2 response to GnRHa, 39 +/- 7 pM/L; range, 18-62; group A; n = 6). Compared to group A subjects, patients in group B had similar (P > 0.2) peak GnRHa-stimulated LH concentrations (B, 4.8 +/- 1 IU/L; A, 2.3 +/- 0.5 IU/L) and peak nocturnal LH (B, 0.81 +/- 0.2; A, 0.25 +/- 0 IU/L), but higher peak GnRHa-stimulated FSH concentrations (B, 26 +/- 7; A, 11 +/- 2 IU/L; P < 0.05) and mean nocturnal FSH (B, 4.2 +/- 1; A, 1.1 +/- 0.3 IU/L; P < 0.05) concentrations. Compared to group B, group C patients had higher (P < 0.001) GnRHa-stimulated peak LH (67 +/- 19 IU/L) and higher (P < 0.05) peak nocturnal LH (9.7 +/- 2.9 IU/L) concentrations, but similar GnRHa-stimulated peak FSH (27 +/- 3 IU/L) and mean nocturnal FSH (3.8 +/- 0.5 IU/L) levels. Group C patients with a ratio of peak GnRHa-stimulated LH to FSH concentrations below or above 1, respectively, had similar peak E2 responses to GnRHa (516 +/- 80 vs. 644 +/- 92 pM/L; P > 0.1). Stepwise regression analysis indicated that the peak LH response to GnRHa (r = 0.76; P < 0.001), but none of the FSH secretory parameters (P > 0.10), affected the E2 response to GnRHa. These data suggest that girls with CPP in the early phase of activation of the hypothalamic-pituitary-gonadal axis are capable of clinically relevant E2 production, which may occur in the face of low LH secretion and low LH/FSH ratios and cannot be explained solely on the basis of increased FSH secretion. Thus, endocrine or paracrine factors other than gonadotropins may be important in amplifying E2 secretion in the early phase of CPP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473395     DOI: 10.1210/jcem.76.4.8473395

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Allopregnanolone levels decrease after gonadotropin-releasing hormone analog stimulation test in girls with central precocious puberty.

Authors:  B Predieri; S Luisi; E Casarosa; E Farinelli; F Antoniazzi; M Wasniewska; S Bernasconi; F Petraglia; L Iughetti
Journal:  J Endocrinol Invest       Date:  2010-06-04       Impact factor: 4.256

2.  Effects of low- and high-intensity exercise training on body composition and substrate metabolism in obese adolescents.

Authors:  S Lazzer; C Lafortuna; C Busti; R Galli; F Agosti; A Sartorio
Journal:  J Endocrinol Invest       Date:  2010-08-31       Impact factor: 4.256

3.  Pharmacokinetic and exposure-response analyses of leuprolide following administration of leuprolide acetate 3-month depot formulations to children with central precocious puberty.

Authors:  Nael M Mostafa; Balakrishna Hosmane; Lois M Larsen; Kristof Chwalisz; Yi-Lin Chiu; Rajendra S Pradhan
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

4.  Gonadotropin-dependent precocious puberty: neoplastic causes and endocrine considerations.

Authors:  Matthew D Stephen; Peter E Zage; Steven G Waguespack
Journal:  Int J Pediatr Endocrinol       Date:  2011-03-06

5.  Evaluation of puberty by verifying spontaneous and stimulated gonadotropin values in girls.

Authors:  Vivian L Chin; Ziyong Cai; Leslie Lam; Bina Shah; Ping Zhou
Journal:  J Pediatr Endocrinol Metab       Date:  2015-03       Impact factor: 1.634

Review 6.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.

Authors:  Katherine A Lewis; Erica A Eugster
Journal:  J Pediatr       Date:  2012-10-03       Impact factor: 4.406

8.  A single sample GnRHa stimulation test in the diagnosis of precocious puberty.

Authors:  Parvin Yazdani; Yuezhen Lin; Vandana Raman; Morey Haymond
Journal:  Int J Pediatr Endocrinol       Date:  2012-07-18

9.  The role of pelvic ultrasound for the diagnosis and management of central precocious puberty: An update.

Authors:  Valentina Talarico; Maria Benedetta Rodio; Antonio Viscomi; Eulalia Galea; Maria Concetta Galati; Giuseppe Raiola
Journal:  Acta Biomed       Date:  2021-11-04

10.  Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy.

Authors:  E Kirk Neely; Lawrence A Silverman; Mitchell E Geffner; Theodore M Danoff; Errol Gould; Paul S Thornton
Journal:  Int J Pediatr Endocrinol       Date:  2013-12-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.